


Crocin-4

Cat. No.:	HY-N10183
CAS No.:	55750-86-2
Molecular Formula:	C ₂₇ H ₃₆ O ₉
Molecular Weight:	504.57
Target:	Reactive Oxygen Species
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>Crocin-4, a carotenoid constituent of saffron, is a potent and brain-penetrant antioxidant agent. Crocin-4 can inhibit the aggregation and the concomitant deposition of Aβ fibrils in the brain. Crocin-4 can be used for the research of Alzheimer's Disease. Crocin-4 also exhibits antitumor and anti-inflammatory activities^{[1][2][3]}.</p>																
In Vitro	<p>Crocin-4 (0.1-1000 μM; 24-72 h) do not compromise cell viability of neuron-like cells^[1].</p> <p>Crocin-4 (1 mM; 72 h) reduces total PSEN1, PSEN1 and PSEN2 complexes, BACE1, APP-C99 and sAPPα, while it increases PSEN1-CTF and PSEN2 in SH-SY5Y-APP cells^[1].</p> <p>Crocin-4 (1 mM; 72 h) suppresses GSK3β and ERK1/2 kinases in PC12-htau cells, and significantly reduces the levels and phosphorylation of tau on the pThr231 and pSer199/Ser202 epitopes^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Differentiated SH-SY5Y-APP cells</td> </tr> <tr> <td>Concentration:</td> <td>1 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td> <p>Significantly reduced total PSEN1 by 19%, and the PSEN1 and PSEN2 complexes by 81 and 65%, while it increased PSEN1-CTF (26%) and PSEN2 (43%).</p> <p>The key molecules of the amyloidogenic pathway, BACE1 and APP-C99 were significantly reduced by 20 and 28%, respectively.</p> <p>The non-amyloidogenic pathway product sAPPα was also reduced, by 44%, while APP-C83 remained unaltered.</p> </td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Differentiated PC12-htau cells</td> </tr> <tr> <td>Concentration:</td> <td>1 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td> <p>Significantly reduced total tau levels (by 32%) and tau phosphorylation (pThr231 and pSer199/Ser202-tau by 22 and 75%, respectively).</p> </td> </tr> </table>	Cell Line:	Differentiated SH-SY5Y-APP cells	Concentration:	1 mM	Incubation Time:	72 hours	Result:	<p>Significantly reduced total PSEN1 by 19%, and the PSEN1 and PSEN2 complexes by 81 and 65%, while it increased PSEN1-CTF (26%) and PSEN2 (43%).</p> <p>The key molecules of the amyloidogenic pathway, BACE1 and APP-C99 were significantly reduced by 20 and 28%, respectively.</p> <p>The non-amyloidogenic pathway product sAPPα was also reduced, by 44%, while APP-C83 remained unaltered.</p>	Cell Line:	Differentiated PC12-htau cells	Concentration:	1 mM	Incubation Time:	72 hours	Result:	<p>Significantly reduced total tau levels (by 32%) and tau phosphorylation (pThr231 and pSer199/Ser202-tau by 22 and 75%, respectively).</p>
Cell Line:	Differentiated SH-SY5Y-APP cells																
Concentration:	1 mM																
Incubation Time:	72 hours																
Result:	<p>Significantly reduced total PSEN1 by 19%, and the PSEN1 and PSEN2 complexes by 81 and 65%, while it increased PSEN1-CTF (26%) and PSEN2 (43%).</p> <p>The key molecules of the amyloidogenic pathway, BACE1 and APP-C99 were significantly reduced by 20 and 28%, respectively.</p> <p>The non-amyloidogenic pathway product sAPPα was also reduced, by 44%, while APP-C83 remained unaltered.</p>																
Cell Line:	Differentiated PC12-htau cells																
Concentration:	1 mM																
Incubation Time:	72 hours																
Result:	<p>Significantly reduced total tau levels (by 32%) and tau phosphorylation (pThr231 and pSer199/Ser202-tau by 22 and 75%, respectively).</p>																

	Downregulates the active and inactive forms of GSK3 β (total GSK3 β by 34%, pSer9-GSK3 β by 30%) and ERK1/2 (total ERK2 by 37%, pERK1 by 40%, pERK2 by 50%).
--	--

In Vivo

Crocic-4 (50 mg/kg; i.p.) is capable of crossing the Blood Brain Barrier (BBB) and build up levels in the mouse brain^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Chalatsa I, et, al. The Crocus sativus Compounds trans-Crocic 4 and trans-Crocetin Modulate the Amyloidogenic Pathway and Tau Misprocessing in Alzheimer Disease Neuronal Cell Culture Models. *Front Neurosci.* 2019 Mar 26;13:249.
- [2]. Koulakiotis NS, et, al. Crocus-derived compounds alter the aggregation pathway of Alzheimer's Disease: associated beta amyloid protein. *Sci Rep.* 2020 Oct 23;10(1):18150.
- [3]. Karkoula E, et, al. Trans-crocic 4 is not hydrolyzed to crocetin following i.p. administration in mice, while it shows penetration through the blood brain barrier. *Fitoterapia.* 2018 Sep;129:62-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA